Zoetis Inc. (FRA:ZOE)

Market Cap	46.14B -39.3%
Revenue (ttm)	8.06B +2.3%
Net Income	2.28B +7.5%
EPS	5.13 +10.1%
Shares Out	n/a
PE Ratio	20.27
Forward PE	18.16
Dividend	1.76 (1.63%)
Ex-Dividend Date	Jan 20, 2026

Volume	n/a
Average Volume	167
Open	108.18
Previous Close	108.02
Day's Range	107.30 - 108.78
52-Week Range	99.45 - 165.16
Beta	n/a
RSI	55.97
Earnings Date	Feb 13, 2026

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and ...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Employees: 14,500
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: ZOE

Financial Performance

In 2025, Zoetis's revenue was $9.47 billion, an increase of 2.28% compared to the previous year's $9.26 billion. Earnings were $2.67 billion, an increase of 7.52%.

Financial numbers in USD